D-PDTC: Diversity patient-derived cancer models to guide precision therapy
Official title: University of California and UT Southwestern D-PDTC
Funded at University of California at Davis · NIH-11473225 · Data updated 2026-11-12
A multi-center effort to create and study 120 diverse patient-derived tumor models to test approved and experimental cancer drugs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $129,653 |
| NIH project number | 3U54CA283766-04S1 |
| Project ID | NIH-11473225 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with advanced cancer from racially and ethnically diverse backgrounds whose tumor tissue can be used to create PDX models.
✕Less likely to help
Patients whose tumors cannot be collected or used for PDX development may not directly benefit.
What this research studies
This project will build a library of diverse patient-derived xenograft (PDX) tumors from people of varied racial and ethnic backgrounds. Researchers will characterize these tumors and use them to test FDA-approved drugs and combination therapies in preclinical studies. The aim is to better understand how cancer develops in different populations and to advance cancer health disparities research. The work brings together six major cancer centers to coordinate PDX development, drug testing, and bioinformatics analysis.
Why it matters
Potential benefit: If successful, the work could lead to more effective, population-inclusive cancer treatments and faster translation of therapies for diverse patients.
How similar studies have gone: PDX programs have shown promise in predicting drug response and guiding personalized therapies, though expansion to diverse populations is ongoing.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Carvajal Carmona, Luis Guillermo — University of California at Davis
- Study coordinator: Carvajal Carmona, Luis Guillermo
Related research
Other NIH-funded projects on the same topics.
-
UC Davis IGA Innovation Center
A research center at UC Davis will study gene-edited livestock to improve animal health, safety, and policy through sharing genetic data and findings about genome edits in cattle, pigs, sheep, and goats.
-
Administrative Core of an equitable breast cancer screening program
A national program headed from UC Davis is coordinating several research efforts to improve how breast cancer screening is done in community settings.
-
The role of novelty and surprise in learning for people with Alzheimer’s disease
A study explores how surprising events affect memory and learning in people related to Alzheimer’s disease, using everyday tasks to see how the brain remembers new information.
-
Understanding how distraction affects students and how to measure it better
This grant studies why distracted students, including those with ADHD, struggle in real-life learning and tests a clearer way to measure distraction in everyday settings.
-
California Partnership for Personalized Nutrition
A California clinical center is testing personalized dietary approaches to improve blood sugar and health for adults with diabetes by using big data and AI to tailor meals.
-
Advancing gastric cancer care for Latinos through patient-derived tumor models
Aimed at Latinos with gastric cancer, this project uses patient-derived tumor models to study how cancer biology and treatments work in real tumors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.